Manurung, Mikhael D.
de Jong, Sanne E.
Kruize, Yvonne
Mouwenda, Yoanne D.
Ongwe, Madeleine Eunice Betouke
Honkpehedji, Yabo Josiane
Zinsou, Jeannot Frézus
Dejon-Agobe, Jean Claude
Hoffman, Stephen L.
Kremsner, Peter G.
Adegnika, Ayola Akim
Fendel, Rolf
Mordmüller, Benjamin
Roestenberg, Meta
Lell, Bertrand
Yazdanbakhsh, Maria
Funding for this research was provided by:
Indonesian Endowment Fund for Education (S-1598/LPDP.3/2016)
Leiden University Medical Center Strategic Fund for Leiden Controlled Human Infection Center
National Institute of Allergy and Infectious Diseases (R01GM9987654)
European and Developing Countries Clinical Trials Partnership (SP.2011.41304.062)
German Ministry of Education and Research
Bontius Stichting
Stichting Tabernaleporis
Article History
Received: 4 December 2021
Accepted: 29 July 2022
First Online: 3 August 2022
Competing interests
: SLH has a financial interest in Sanaria Inc., which is the developer and owner of PfSPZ Challenge and the sponsor of the clinical trial. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors declare no competing interests.